- Oncotype DX
- Boceprevir/ Telaprevir
- Biosimilars & HCPCS Coding
- Xgeva coverage policies
- Makena (hydroxyprogesterone caproate)
- Grandfathering or NOT for MS interferons
- Egrifta coverage
- Prolia policy coverage/criteria review in PMO
- Retreatment Indication for Infergen
- Stelara medical vs pharmacy coverage
- Collagenase Clostridium Histolyticum
- Arcalyst and Ilaris policy comparison
- Cerezyme shortage
- Botulinum toxin policy compare for off-label indications
- Botulinum toxin policy compare for on-label indications
- Xolair split vial issue
- Re-treatment with pegylated interferons in hepatitis C
- Reclast policy criteria
- Synagis policy criteria for respiratory syncytial virus (RSV)
- Coverage of Cinryze
- Biologic agents for ankylosing spondylitis - policy criteria
- Definition of self-injectable
- Upper limit IgE levels for Xolair use
- Remicade for ulcerative colitis - policy criteria
- Biologic agents for Rheumatoid Arthritis - policy criteria
- Biologic agents for Crohn's disease - policy criteria
- Coverage of TSP's (Nplate and Promacta)
- Interferons and definition of compensated liver disease
- Byetta as monotherapy
- Biologic agents for psoriasis - policy criteria
- Leukine Supply
- Spike in utilization of insulins
- Tysabri policy criteria - Crohn's disease
- Tysabri policy criteria
- Zostavax in patients under 60 years of age
- Forteo policy criteria
- Medicare coverage of Zostavax
- Stimulation tests for growth hormone
- Infergen in peg interferon failures
- Shingles vaccine in retail
- IV product for fibromyalgia
- Growth hormone for a new member with cranial irradiation